Anacor Pharma (ANAC) Tops Q4 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Anacor Pharmaceuticals (ANAC) PT Raised to $57 at Jefferies
March 13, 2015 8:41 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and lifted is price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $57.00 (from $41.00) following Q4 results.
Steinberg commented, "ANAC reported a narrower Q4 loss primarily due to the earlier recognition of Kerydin revs (see details). More... More
Anacor Pharmaceuticals (ANAC) PT Raised to $60 at Wedbush
March 13, 2015 7:13 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $60.00 (from $50.00) after in 4Q14, its first full quarter of sales, Kerydin achieved about $10M in sales, beating the firm's $7.8M estimate.
Nierengarten commented... More
